Brian Keroack, MD
Rheumatology · Portland, MENPI 1891788659
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $266 of the $346 with a category attached, or 76.9%. United Therapeutics Corporation accounts for 72.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $250 and has fallen 93.5% since, to $16 in 2025.
Across 4 payments — averaging $86.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$250
- Johnson & Johnson$80
- Genentech USA, Inc.$16
What the payments were for
- Food & beverage$26677%
- Education$8023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 2 | $250 |
| Johnson & Johnson | 1 | $80 |
| Genentech USA, Inc. | 1 | $16 |
How this compares
$346 in reported general payments places this provider in the 60th percentile of 28 rheumatology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 260 | $2,013,012 |
| Humira(Cf) PenAdalimumab | 168 | $1,440,447 |
| Xeljanz XrTofacitinib Citrate | 115 | $696,025 |
| EnbrelEtanercept | 82 | $644,595 |
| RinvoqUpadacitinib | 51 | $408,843 |
| Humira(Cf)Adalimumab | 28 | $190,724 |
| XeljanzTofacitinib Citrate | 26 | $160,227 |
| Actemra ActpenTocilizumab | 26 | $121,623 |
| Taltz AutoinjectorIxekizumab | 12 | $81,560 |
| AvsolaInfliximab-Axxq | 13 | $52,962 |
| ActemraTocilizumab | 12 | $52,720 |
| Hydroxychloroquine Sulfate | 331 | $18,963 |
| MethotrexateMethotrexate Sodium | 564 | $12,732 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 196 | $7,981 |
| Celecoxib | 113 | $7,033 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Portland
- Brian DaikhPortland$300
- Stephanie Gartner-FanburgPortland$152
- Edward FelsPortland$57
- Joshua KellerPortland$14
- Katherine KellerPortland$0
- Kenneth OrourkePortland$0
- Charles RadisPortland$0
- Erik OconnellAugusta$27K
- Kenneth CalamiaBelfast$11K
- Nancy-Nichole BarryBelfast$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.